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Abstract 
PURPOSE:  The number of effective knee osteoarthritis (OA) interventions, especially those 
tailored to specific compartmental involvement, is small. The objective of this study was to 
determine the efficacy of a realigning patellofemoral (PF) brace in improving pain and function 
among persons with symptomatic lateral patellofemoral OA.   
METHOD:  We conducted a double blind, randomized crossover trial of a realigning PF brace 
for persons with lateral PF OA. Participants had lateral PF OA with anterior knee symptoms on 
most days of the month, lateral PF joint space narrowing, and radiographic evidence of a 
definite osteophyte in the PF joint.  We compared two treatments: A) Control treatment 
consisting of a BioSkin Q Brace with patellar realigning strap removed; and B) Active treatment 
consisting of a realigning BioSkin Q Brace with the strap applied. For each participant, the trial 
lasted 18 weeks, including 6 weeks each of active and control treatment period separated by a 
6-week washout period. The order of treatments was randomized. The primary outcome was 
change in knee pain on the visual analog scale (VAS). Secondary outcomes included WOMAC 
pain, function, and stiffness. An unstructured correlation matrix for observations within 
participants was used in generalized estimating equation fitting to derive a linear regression 
model that expressed the relation between the intervention and change in VAS pain. 
RESULTS: 80 participants (63 F) with a mean age and body mass index of 61 years and 28 
kg/m2, respectively, were randomized by order of treatment. A model examining the main effects 
for change in VAS knee pain (0-100) demonstrated no significant treatment effect (-0.68 VAS 
units, 95% CI: -6.2, 4.8 units, p=0.81) and no differential carryover effect. There was also no 
significant difference between active and control treatments for WOMAC pain, function, or 
stiffness outcomes. 
CONCLUSION: The effects of a specific realigning patellofemoral brace are not of clinical or 
statistical significance. 
NIH Clinical Trials Registry NCT00381563 
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Introduction 
The patellofemoral (PF) joint is involved in approximately 65% of persons with knee OA; 
predominantly within the lateral PF compartment [1,2]. Relatively little attention has been paid to 
the PF joint in knee OA, despite suggestions that disease in this compartment may be strongly 
correlated with lower extremity disability [3], and that involvement of the PF joint is more highly 
correlated with knee pain in OA than is isolated involvement of the tibiofemoral (TF) joint [4-6]. 
Unfortunately, the majority of epidemiologic studies examining risk factors for OA have focused 
on the TF joint with little heed paid to the unique biomechanics of the PF joint [7-9]. This line of 
research is needed as the designs of the PF and TF compartments reflect unique functions and 
mechanics [10]. These differences in design and function are likely to have important 
implications for treatment. Given the heterogeneity of OA as a disease process and its protean 
symptomatic presentations, therapeutic interventions for knee OA should be guided by an 
awareness of which joint compartments are involved. At present, there are few effective 
conservative interventions for relieving pain and improving function in knee OA and even fewer 
that are specifically targeted to the unique mechanics of the PF compartment.  
Patellar malalignment is a translational or rotational deviation of the patella that may lead 
to an aberrant dispersion of forces transmitted through the PF joint [11]. Patellar malalignment 
may cause an aberrant dispersion of patellofemoral joint reaction (PFJR) forces and, by this 
mechanism, predispose to pain and/or structural damage [11-13]. Of primary concern is 
excessive lateral translation in the coronal plane and excessive lateral tilt in the axial plane [14]. 
Uncontrolled data suggests that patellae that are well-aligned centrally in the trochlear groove, 
without lateral coronal or axial malalignment, may be less likely to develop osteoarthritis [15-17]. 
Conversely, persons with lateral PF OA often present with laterally malaligned patellae and 
maltracking that is associated with symptoms [18]. Prior studies have demonstrated that patellar 
taping can lead to marked short-term improvements in knee pain [19,20] although it is not 
altogether clear that the mechanism involves substantive changes in patellar alignment [21-28]. 
One possible explanation of the favorable influence that patellar taping has on symptoms is that 
it leads to sufficient improvements in patellofemoral alignment (by reducing lateral displacement 
and tilt) to improve joint contact area and consequently impact joint stress. Some evidence 
suggests that realigning patellofemoral braces can lead to similar short-term improvements in 
joint contact area [23,24].  
Given the increased likelihood of patellar malalignment in people with PF OA and the 
link between malalignment and symptoms, interventions that aim to improve patellar alignment 
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may be efficacious. If one were able to improve PF alignment with application of a 
patellofemoral brace with a realigning strap in persons with PF OA, similar improvements in 
symptoms to those seen in response to patellar taping may be possible [3,29]. Despite its 
proven efficacy, patellar taping [30] has not been widely adopted clinically for the treatment of 
patients with knee OA [19,20]. This probably results from the fact that it is complicated to 
administer and often difficult for older patients to apply independently. Skin irritation occurs in a 
significant minority of individuals, and removal of the adhesive tape is often uncomfortable for 
patients with body hair. Furthermore, there are no studies assessing the longer-term efficacy of 
patellar taping. In contrast, realigning PF braces may accomplish many of the mechanical 
effects of patellar tape, while avoiding these limitations. More specifically, PF braces are easy to 
apply during long-term repeated use, and are far less likely to cause skin irritation.  
Given the pressing need for effective interventions for PF OA, the specific aim of this trial 
was to undertake a double-blind, randomized crossover clinical trial among patients with PF OA 
to determine whether use of a realigning PF brace for 6 weeks leads to greater pain reduction 
than does an equivalent period of use of the same brace without a patellar realigning strap. 
Methods 
Participants 
From March 2006 to December 2009, we recruited persons with lateral PF OA from 
previous trial databases in which participants had been originally recruited from community 
volunteers. Participants were required to have knee pain on most days and either isolated 
lateral PF OA or mixed lateral PF and TF OA.  Participants had skyline and bilateral standing 
AP radiographs during the screening phase.  We used a radiographic definition of PF OA from 
the skyline view and adopted scoring criteria that have been previously described [31]. Briefly, 
individual radiographic features and overall grades of OA in the PF compartment were read 
according to the following schemes using the OARSI atlas; joint space narrowing (JSN) and 
osteophytes, both on 0–3 scales. A knee was defined as having PF OA if there was an 
osteophyte of severity grade ≥2  OR if there was moderate to severe JSN (grade ≥2 ) with 
concurrent grade 1 osteophyte in the PF joint [31]. We recruited persons with predominantly 
lateral PF OA; defined as lateral > medial patellofemoral JSN on skyline view. 
PF OA was defined as compartment-specific (or isolated) if there was not concomitant 
TF OA. Radiographic TF OA was defined as a Kellgren and Lawrence (K/L) grade of ≥2 on the 
AP view [32]. Participants with concomitant TF OA (in addition to radiographic lateral PF OA) 
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were admitted if their source of symptoms for self-reported pain location or physical examination 
was consistent with PF disease. The judgment was based on consideration of: (1) Which 
activities brought on the knee pain; pain on stair climbing and/or rising from a chair was 
considered typical of PF OA, whereas pain walking on level ground was considered more typical 
of the TF joint; (2) Where the pain was located in the knee; Pain in the posterior aspect of the 
knee or in the region of the pes anserine bursa was considered unlikely to be from the PF joint; 
and (3) Where tenderness was located on examination; Tenderness with patellar mobilization 
was considered typical of PF OA.  
For participants in whom both knees met the eligibility criteria, we treated the more 
symptomatic of the two knees to optimize symptom attribution for self-reported assessments.  
Exclusion criteria included:  
1. Bed or wheelchair bound persons or persons who usually used an ambulation aid to 
walk, such as a cane, crutch, or walker.  
2. Lower extremity pain emanating from the back or hip more than from the knee as 
determined by screening questionnaire and physical examination. 
3. Low initial pain score on VAS (<4 out of 10) on phone screening and visit 1 screening 
(Note: bracing commenced after screening and randomization) 
4. Planning to move from area within 10 months of study screening or had any extended 
vacation plans of more than 1 month during the study period 
5. Symptomatic comorbid disease that limited activities more than knee pain (such as heart 
or lung problems) per screening questionnaire. 
6. Receiving corticosteriod injection in the month prior to starting the trial, or hyaluronan 
injection in the 6-month period prior to the trial.   
7. Bilateral total knee replacements or plan for total knee replacement in next 6 months for 
the signal knee. 
8. Likely difficulty with brace fitting or brace slippage due to knee or thigh dimensions 
inappropriate for brace fitting (knee circumference > 55cm). Prior prescription brace use 
or allergies to neoprene. 
9. Other known causes of arthritis, including rheumatoid arthritis, systemic lupus erythema, 
gout, psoriatic arthritis, or pseudogout as determined by self reported diagnosis. 
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10. Skin breakdown at the site where the brace was to be applied. 
11. Failure to pass run-in test or unable to properly fit the brace during the run-in period.  
12. Inability to complete the self-reported forms in English. 
Procedures  
We performed a randomized, crossover, double-blind (participant and assessor) 
controlled trial. It was prospectively registered with the NIH Clinical Trials Registry 
NCT00381563. The Boston University IRB and New England Baptist Hospital Human Research 
Ethics Committee approved the study and all participants provided written informed consent. 
IRB approval was obtained on July 13th 2006, the first participant was enrolled in December 
2006 and the last participant completed the study on November 3rd 2009.  
The trial included a run-in period in which there was a screening phone call, a visit two 
weeks later (pre-randomization screening visit), and a randomization visit 2 weeks after the 
initial visit. During the 2-week run-in period, participants wore a circumferential, elastic brace 
strap with an attached New Lifestyles NL-1000 accelerometer (New Lifestyles, Inc, Lees 
Summit, MO) to monitor usage. Participants were instructed to wear the brace strap for a 
minimum of 4 hours per day, and to record their perceived usage in a participant log[33]. After 
the run-in showed acceptable usage (defined as wearing brace for at least 4 hours per day) and 
following baseline outcome assessment, patients were randomized to receive either Treatment 
A or Treatment B first for 6 weeks, followed by a 6 week wash-out period before crossing over 
to the other treatment group (B or A) for the second 6 week period of treatment.   
Randomization was performed outside of the clinic by a biostatistician and concealed 
from all other study investigators. Randomization was stratified by the presence or absence of 
x-ray TF OA and by gender, as there may be differences in symptom and disease location by 
gender [3]. We preserved allocation concealment by having the randomization codes held by 
the biostatistician external to the clinical trial operations. Group allocation was revealed from a 
sealed envelope to the research coordinator at the time of the randomization visit.  
Intervention 
The goal of this study was to evaluate the therapeutic effects of a realigning 
patellofemoral brace in comparison with a non-realigning placebo brace. The two treatments 
were: TREATMENT A (CONTROL) a BioSkin Q Brace (Cropper Medical Inc., Ashland, OR) with 
the realigning T strap removed and TREATMENT B (ACTIVE) the BioSkin Q Brace with the 
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realigning T strap intact (see Figure 1).  Participants were asked to wear the assigned knee 
brace for a minimum of 4 hours per day during the treatment period.  
The Q Brace™ has an anterior aperture to admit the patella. The “T” strap has two arms 
that adhere medially with Velcro and has one attachment laterally. The application is intended to 
control the direction of traction on the patella. In particular, the strap aimed to apply a medial 
glide to minimize lateral movement of the patella. The brace is made of a material trademarked 
as Bio Skin®. Bio Skin® is an elastic, latex free, hypo-allergenic material that provides 
compression and moisture vapor transfer. The Q Brace can be purchased off-the-shelf in a 
range of sizes for different knee and thigh circumferences. In this study, fitting and positioning of 
the knee brace was performed by a trained investigator (KH) who also positioned and applied 
the “T” strap. Marks were placed on the brace to indicate where the “T” strap should be 
reapplied for daily use. The person teaching the participant how to correctly apply the brace 
was, by necessity, not blinded. 
  
 
Figure 1. BioSkin Q Brace with the realigning T strap intact (Figure Left). Positioning 
and configuration of the T strap overlying the brace delineated in red with patella aperture facing 
anteriorly and strap cupping the lateral aspect of the patella for application of a force to produce 
a medial patellar glide (Figure Right). 
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In all other respects, we attempted to conduct a blinded trial. Our description of the 
treatments to the participants was that we were comparing two types of braces for their PF OA 
without specifying which one constituted active treatment. The active and control braces were 
also identical apart from the application of the realigning T strap.  
Trial Outcomes 
All participants were evaluated by the same blinded assessor. The primary outcome was 
change in knee pain on the visual analogue scale (VAS) scale. Participants rated the average 
severity of knee pain over the previous week. Change in pain was measured on a 0–100mm 
horizontal VAS with terminal descriptors of (0 = no pain; 100 = maximal pain) [34]. This was 
assessed at baseline and at each follow-up visit (week 1, 3 and 6 of each treatment phase). 
Secondary Outcomes included: 
1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) 
Pain Subscales (Likert form) [35] (primary treated Knee). Pain was assessed using the 
pain subscale of the Likert version of the WOMAC. This disease-specific measure is 
reliable, valid and responsive and consists of 5 pain items, 17 function items and 2 
stiffness items each using a 5- point scale to score each item, where higher scores 
indicate worse symptoms [35].  
2. WOMAC Function Subscale. Difficulty with physical function was 
assessed using the physical function subscale of the Likert version of the WOMAC.  
3. WOMAC Stiffness Subscale Stiffness was assessed using the stiffness 
subscale of the Likert version of the WOMAC.  
Adherence 
We used a number of different methods to monitor and improve adherence. First, we 
screened participants during the run-in after using the brace strap and accelerometer to assess 
whether they were willing to wear the brace therapy for their PF OA. Second, we inquired in a 
detailed fashion about adherence with use of bracing and evaluated the participant's log of 
brace usage at each visit.  We called the participants every week during the active phases of 
the trial (0-6 weeks; 12-18 weeks).  
Statistical Analysis 
Analysis of the trial focused on the primary outcome measure, change in pain during 
treatment. The purpose was to estimate the effect of a realigning strap on pain reduction in 
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comparison with a control brace. Because there were repeated assessments of the VAS and 
WOMAC pain scores within each treatment period, we averaged the mid-treatment (week 3 of 
each treatment phase) and end of treatment (week 6 of each treatment phase) pain scores to 
reduce the variability of assessment [36]. Based on taping studies that showed immediate 
effects on symptoms, we expected the effects of the PF brace to fully manifest after 3 weeks of 
treatment, so averaging of mid-treatment and end of treatment pain scores should not have 
biased estimates of treatment effect. 
We performed regression analysis of the pain scale measures using a linear mixed-
effect model with unstructured covariance structure for repeated measurements within 
participants. In these regression models, the baseline score of each phase was used as a 
predictor in addition to indicators of treatment and period and an interaction of treatment by 
period. In a two-period crossover trial, the treatment by period interaction is equivalent to the 
carryover effect, so this provided another method of assessing the carryover effect. The 
treatment effect in this analysis would have been diminished if there was a carryover effect of 
the first treatment. However, the washout period of six weeks between treatments was intended 
to remove any such carryover effect. We also used a formal statistical test to assess for 
carryover effect [37]. This analysis approximated an intent-to-treat approach with the last 
observation brought forward for missing values. 
The secondary analysis of pain, function and stiffness using the WOMAC subscales 
proceeded in the same manner as is outlined for the pain scale above. We also performed the 
crossover analysis stratified by form of OA: participants with isolated PF OA in one stratum and 
those with TF involvement in the other stratum [38].  
All statistical analyses were performed using version 9 of the SAS statistical analysis 
software package.  
Power estimates 
Based upon the results from the Hinman [19], Horlick [39] and Kirkley [40] studies of 
knee taping and bracing, we anticipated a conservative treatment effect difference of 30% in 
pain and function. We estimated a correlation of 0.6 in the primary outcome measure (VAS 
pain) for measures taken within a participant. In all of these calculations we used the 
comparison between the therapeutic tape and control tape groups. Hinman et al[19] found a 
significant difference between the treatments for VAS pain with a mean difference of 1.3 on a 10 
cm scale.  
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We also planned an a priori stratified analysis for PF OA and mixed PF and TF OA to 
assess for differences in treatment effect between these two groups. For VAS pain in a 
crossover analysis, just under 45% of the participants would need to have isolated PF OA to 
detect a treatment difference of 0.7cm on the VAS (0-10cm scale) with 80% power (2 sided 
alpha, p = .05). In the analysis of all participants, a treatment difference of 0.46 in VAS pain was 
detectable with 80% power. To achieve 80% power to detect a difference of 0.7, 43% of 
participants would need to have isolated PF OA. To achieve 80% power to detect a difference of 
0.9, 26% of participants must have isolated PF OA. Thus, in order to be conservative we 
recruited 40 persons with isolated PF OA 
As we were interested in both the crossover design and phase 1 analysis, we assessed 
the power with 80 participants to assess difference in each. The treatment differences on a 0-
10cm VAS where the power reaches 80% were as follows: difference in VAS pain detectable 
with cross-over analysis approach = 0.46, and difference in VAS pain detectable with period 1 
analysis approach = 1.30. 
Results 
Of the 592 potential participants who were contacted by phone, 145 were eligible for a 
screening visit. The major reasons for ineligibility on phone screening was insufficient pain 
(n=125), prior brace use (n=88), current cane or walker use (n=60), and a prior diagnosis of 
another cause of osteoarthritis (n=58). Of the 145 participants who had a screening visit, 80 (40 
with isolated PF OA and 40 with mixed PF and TF OA) were found to be eligible and were 
randomized.  The most common reason for ineligibility at the screening visit was failure to fulfill 
radiographic entry criteria (n=57). Sixty seven participants (84%) completed the 18-week trial. 
Figure 2 shows the flow of participants through the trial.  
Forty-one participants were randomized to receive the active brace first and 39 to 
receive the control brace first. There were no statistically significant differences in age, gender, 
BMI, radiographic severity or baseline VAS pain or WOMAC pain score between these two 
treatment order groups (Table 1). The median Kellgren and Lawrence grade and lateral PF JSN 
grade for the study sample signal knee were both 2. Demographic and clinical characteristics of 
the 13 participants who withdrew from the study did not differ substantially from those who 
remained (data not shown). 
When analyzing the crossover trial findings, we first tested for treatment period and 
differential carryover effects (Table 2 & Figure 3). The treatment effect of the realigning strap 
was not significant for VAS pain with a 3.71 unit difference (95% CI-7.23, 14.65). The differential 
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carryover was a 7.7 unit difference in the VAS pain score (P= 0.36), showing that the 
comparison of treatment efficacy was not significantly different if the patients were randomized 
to the active or control brace first. Therefore, we removed the carryover term from the model. In 
Model 2, after excluding the differential carryover effect and adjusting for baseline pain score, 
the active intervention had no significant effect on VAS pain with a -0.7 unit (-0.07cm) difference 
(95% CI: -6.2, 4.8 units; p=0.81). The study was powered to detect a 0.7cm on the VAS (0-
10cm scale) which is still less than that which is clinically significant [41,42]. 
Further examination of the effects of PF bracing on WOMAC pain (Table 2b and Figure 
4), WOMAC Function (Table 2c) and WOMAC Stiffness (Table 2d) revealed similar results with 
no significant carryover effect and no significant treatment effect. In Model 2, after excluding the 
differential carryover effect and adjusting for baseline WOMAC pain score, the active 
intervention had no significant effect on WOMAC pain with a -0.11 unit difference (95% CI: -0.66, 
0.88 units; p=0.77). Similar effects were seen for WOMAC function -0.02 unit difference (95% 
CI: -2.83, 2.79 units; p=0.99) and WOMAC stiffness -0.11 unit difference (95% CI: -0.53, 0.32 
units; p=0.61). 
Table 3 shows that the average participant was adherent (self-reported from diary) with 
a mean of 4.8 hours per day of use in the active brace and 4.3 hours per day for the control 
brace. Most participants wore the brace for more than 3 hours per day. The adverse events 
were generally minimal with no substantive differences between interventions. However, 4 of 
the people who withdrew from the study cited increased knee pain and/or foot/ ankle swelling 
and 2 people withdrew due to fitting issues. None of the remaining participants who experienced 
an adverse event in the trial required either increased analgesia or withdrawal of the brace. 
Additional analyses limited to phase 1, determining the effect of isolated PF OA vs. 
mixed PF and TF OA, in addition to effects of gender showed results consistent with those 
already presented and are not further presented here. 
Discussion 
The development of efficacious, conservative, non-pharmacologic treatment approaches 
that are capable of ameliorating the symptoms and improving the structure of knee OA is an 
important research objective [43]. Despite their current under-emphasis in clinical trials and 
practice, therapies targeting the pathomechanics of OA are likely to be efficacious [44]. 
Unfortunately, we have not found any therapeutic clinical effects from the application of a brace 
with a realigning strap designed to improve PF alignment in persons with lateral PF OA 
compared with an identical brace without the realigning strap. Although participants were 
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adherent to the intervention in this trial and the application of the brace was generally well-
tolerated, there was little therapeutic benefit to be gained by the addition of a realigning strap to 
the brace. 
The underlying aim of this study was to assess the patellar realigning effect of the strap 
on symptoms. The rationale behind this is that people with lateral PF OA have altered alignment 
(including lateral displacement and tilt) and that this maltracking is associated with symptoms 
[18]. Hence if we were to correct maltracking, we should see a reduction in symptoms. This trial 
demonstrated that the addition of a realigning strap did not lead to a reduction of symptoms 
compared to the same brace without the strap. There are a number of possible reasons why this 
may be the case and why we have found no significant treatment effect in this trial. 
Prior studies have demonstrated that knee taping improves pain [30], but it is not clear 
that the mechanism  involves a substantive change in patellofemoral alignment. Despite 
numerous investigations of the potential mechanism of the therapeutic effect of taping and 
bracing in patellofemoral pain syndrome, a condition thought to result from maltracking of the 
patella, the reasons for a favorable influence of both taping and bracing on symptoms remains 
unclear [21-28]. Some of these studies [23,24], using dynamic MRI to visualize PF kinematics in 
persons with patellofemoral pain syndrome, have suggested that bracing may improve joint 
contact area and as a consequence reduce PF joint stress. However, these studies [23,24] were 
in younger persons with patellofemoral pain syndrome and thus they are not immediately 
generalizable to persons with PF OA. Crossley et al [45] conducted the only study evaluating 
effects of taping on patella alignment in people with OA and showed that changes in patellar 
alignment occurred immediately following tape application. Whether these changes persist 
following prolonged use of the tape when stretching and loosening is likely to occur is not 
known. 
This said, the relation between PF alignment and pain has been demonstrated in a 
number of studies but is not strong in any of them [18]. Thus if one were able to modify PF 
alignment with application of a realigning strap (such as in this study) it may have little influence 
on symptoms.  
It may be that the application of the realigning strap was not successful in improving 
contact area and reducing joint stress. The aperture on this brace for positioning of the patella 
was quite small. As such, it is possible that the brace alone without the strap actually applied 
compressive force to the anterior aspect of the patella, increasing retropatellar contact force 
and, in so doing, mitigating any reduction in symptoms.  
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It is important that we clearly state that we have demonstrated that the application of this 
specific brace was no more effective than the control brace in relieving symptoms for people 
with PF OA. This does not reflect any potential benefit in persons with PF pain from other 
causes nor for other types of PF braces.   
There are a number of limitations of this study that warrant description. There was no 
control group without a brace for comparison to the intervention because of concerns about 
unblinding.  Prior research has highlighted the difficulty of disentangling the placebo effect in 
non-pharmacologic clinical trials [46-48]. Consistent with this prior research, participants in our 
trial demonstrated improvements in symptoms during both the control period (brace without a 
realigning strap) and the active intervention period (brace with the realigning strap), but we were 
unable to detect a significant difference between the two treatment periods. 13 (16%) 
participants dropped out of the study potentially leading to a loss of statistical power and 
introducing the potential that the null study findings and conclusions may be due to type-2 error. 
We also lacked sufficient power to stratify based on severity of lateral PF joint space narrowing 
at baseline to see if there was differential benefit. The variability of the outcomes in this study, 
reflected in the wide confidence intervals for the main effect indicates some uncertainty in the 
outcome. The principal finding did not detect a suggestion of a treatment effect with the active 
intervention having no significant effect on VAS pain with only -0.7 units (0.07cm) difference 
(95% CI: -6.2, 4.8 units or -0.62cm to 0.48cm). This treatment difference is much smaller than 
that which is clinically relevant. According to Angst, a clinically relevant difference in VAS pain is 
1.2cm or 12 units [41,42]. The attribution of symptoms to the PF or TF joint is challenging and 
our classification of those with predominant PF involvement could lead to misclassification. 
Lastly, the daily duration of treatment required to mechanically re-align the patella is unknown, 
and therefore the prescribed 4 hours of daily use in this study was largely arbitrary. In the clinic, 
braces are often prescribed for use only during aggravating weight bearing activity as opposed 
to a set time of 4 hours per day. Furthermore, we do not know if the patient population in this 
study had PF malalignment. 
Another possible reason for not finding an effect of bracing is that the primary outcome 
measure may not have been responsive enough to detect changes in knee pain among persons 
with PF OA. Our primary outcome was a global measure of knee pain during the previous week. 
It is possible that a change in pain would have been more evident if pain had been rated only 
when people were wearing the brace, or if pain had been rated only during weight-bearing 
activities when the mechanical effects of the brace are most likely. Further some of the 
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participants pain at the time of study commencement (as opposed to at time of phone and visit 
screening) was less than 4 on the 0-10 VAS scale potentially mitigating detecting a treatment 
effect. 
Given prior studies demonstrating a positive effect of taping, it is interesting to theorize 
as to why braces would not work to a similar extent. We assumed that the realigning strap 
would have a similar mechanical effect to taping (the application of a medially directed force). 
There are some differences in the studies of taping to our bracing study that may lead to 
differences in the effects seen during these reported trials [19,20,30,45]. Tape was left on full-
time for a week so it is unlikely that there is a lasting force once the tape stretches and loosens 
within the first day. In contrast, the brace was used ~4 hours per day, during which time the 
applied force is likely to be nearly continuous with use. Despite educating participants about the 
appropriate application of the brace and assessing performance at each study visit, repeat 
donning of the brace at home may not have been consistent. In contrast, once the tape is 
applied it remains on and in that position until removed. Our study selectively recruited persons 
with PF OA whereas the prior PF taping studies in OA recruited persons with OA in any portion 
of the knee joint. However this should have led to a more favorable opportunity for our trial to 
have detected an effect. Perhaps other features of the application of tape, including the 
individualized application of tape by a trained therapist and the potential to reduce fat pad 
impingement by taping may also be helpful. 
There are also a number of important strengths of this study that merit mentioning. All 
participants had meaningful symptoms at baseline, suggesting an opportunity for detecting a 
real treatment effect if there was a treatment effect to be detected. Similarly, this study was 
adequately powered to detect a clinically meaningful treatment effect on the primary outcome 
measure. In addition, we specifically recruited only persons with PF OA into this study cohort 
using stringent selection criteria. Other studies of patellar taping have recruited persons with 
tibiofemoral OA. Finally, the crossover design of this trial facilitated both efficient recruitment 
and strong protection against bias due to patient-related factors. 
In conclusion, this study did not demonstrate measurable clinical significance of a 
realigning strap on a patellofemoral brace in reducing pain among persons with lateral PF OA.   
This trial represents the results of a test of one brace in persons with lateral PF OA and does 
not mitigate the potential for other PF braces to have a therapeutic effect on this disease. 
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Figure 2. Flow chart of participants 
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Table 1. Baseline participant characteristics according to assigned initial treatment  
 
Characteristics Active Brace 
to Control 
brace (n=41 ) 
Control 
brace to 
Active brace 
 (n=39 ) 
Age, mean SD years 60(9.7) 61(9.1) 
Male sex, % 9 (22.5%) 8 (20.5%) 
Body mass index, mean SD kg/m2 27.7(12.5) 27.4(14.0) 
Kellgren/Lawrence grade ≥2, %  24(58.5%) 21(53.8%) 
VAS† pain score, mean SD (0–100 scale) 45.2(27.4)  
range: 1-100, 
Median: 38. 
35.4(24.8) 
range: 1-87, 
Median: 26. 
WOMAC* pain score, mean SD (0–20 scale) 7.8(3.6) 7.2(3.9) 
Kellgren and Lawrence Grade signal knee: 
Median {range} 
2(0-4) 2(0-4) 
n (%) Grade 0 7(17%) 8(21%) 
n (%) Grade 1 10(24%) 10(26%) 
n (%) Grade 2 6(15%) 6(15%) 
n (%) Grade 3 13(32%) 10(26%) 
n (%) Grade 4 5(12%) 5(13%) 
Lateral PF Joint Space Narrowing Grade signal 
knee: Median {range} 
2(0-3) 2(0-3) 
n (%) Grade 0 3(7%) 3(8%) 
n (%) Grade 1 17(41%) 14(36%) 
n (%) Grade 2 11(27%) 15(38%) 
n (%) Grade 3 10(24%) 7(18%) 
† VAS-Visual Analog Scale pain score at commencement of bracing 
* WOMAC- Western Ontario and McMaster Universities Osteoarthritis Index. 
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Table 2a. Predictors of VAS pain scores during the crossover trial* 
Predictor Model 1  Model2 
Baseline VAS pain score  
(95% confidence interval) 
p-value 
0.55 
(0.41, 0.68) 
<0.0001 
0.56 
(0.43, 0.69) 
<0.0001 
Treatment  
 (95% confidence interval) 
p-value 
3.71 
 (-7.23, 14.65) 
0.5010 
-0.68 
(-6.20,4.84) 
0.8055 
Treatment, period 1 vs. period 2  
(95% confidence interval) 
p-value 
0.89 
(-9.33,11.11) 
0.8627 
-3.06 
(-8.82, 2.71) 
0.2934 
Period by treatment interaction †  
 (95% confidence interval) 
p-value 
7.70 
(-8.89, 24.29) 
0.3573 
 
 
* Values for model predictors are beta coefficients. For treatment as a predictor, a value of x 
means that active treatment was associated with a x lower score on the VAS pain scale 
compared with control treatment. An unstructured correlation matrix for observations within 
participants was used in generalized estimating equation fitting of the marginal model (1). Model 
2 was conducted with exclusion of the differential carryover effect. 
† Tests whether treatment effects differed according to use in period 1 or period 2, constituting 
the differential carryover effect. 
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Table 2b. Predictors of WOMAC pain scores during the crossover trial* 
Predictor Model 1  Model2 
Baseline WOMAC pain score  
(95% confidence interval) 
p-value 
0.56 
(0.43, 0.69) 
<0.0001 
0.58 
(0.45, 0.71) 
<0.0001 
Treatment   
(95% confidence interval) 
p-value 
1.33 
(-0.22, 2.88) 
0.0912 
0.11 
(-0.66, 0.88) 
0.7744 
Treatment, period 1 vs. period 2  
(95% confidence interval) 
p-value 
1.24 
(-0.19,2.67) 
0.0877 
0.16 
(-0.62, 0.94) 
0.6883 
Period by treatment interaction †  
 (95% confidence interval) 
p-value 
2.17 
(-0.24, 4.57) 
0.0769 
 
 
Table 2c. Predictors of WOMAC function scores during the crossover trial* 
Predictor Model 1  Model2 
Baseline WOMAC function score  
(95% confidence interval) 
p-value 
0.80 
(0.69, 0.92) 
<0.0001 
0.81 
(0.70, 0.92) 
<0.0001 
Treatment  
 (95% confidence interval) 
p-value 
0.70 
(-4.62, 6.01) 
0.7943 
-0.02 
(-2.83,2.79) 
0.9878 
Treatment, period 1 vs. period 2  
(95% confidence interval) 
p-value 
-1.01 
(-5.59, 3.57) 
0.6620 
-1.57 
(-4.59, 1.46) 
0.3056 
Period by treatment interaction †  
 (95% confidence interval) 
p-value 
1.10 
(-5.74, 7.93) 
0.7499 
 
 
Table 2d. Predictors of WOMAC stiffness scores during the crossover trial* 
Predictor Model 1  Model2 
Baseline WOMAC stiffness score  
(95% confidence interval) 
p-value 
0.65 
(0.52, 0.78) 
<0.0001 
0.67 
(0.54, 0.80) 
<0.0001 
Treatment  
 (95% confidence interval) 
p-value 
0.23 
(-0.49, 0.95) 
0.5293 
-0.11 
(-0.53, 0.32) 
0.6129 
Treatment, period 1 vs. period 2  
(95% confidence interval) 
p-value 
0.26 
(-0.39, 0.91) 
0.4256 
-0.02 
(-0.46, 0.42) 
0.9314 
Period by treatment interaction †  
 (95% confidence interval) 
p-value 
0.55 
(-0.41, 1.51) 
0.2548 
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Table 3. Adherence to and side effects of treatment 
 
 Active brace  Control 
brace   
Adherence, mean SD 
hours of wear/day from self report in diary 
  
Period 1 Mean(SD) 4.77(2.07) 4.32(2.28) 
n (%) <1 hr 1(3%) 3(9%) 
 n (%) 1-2 hrs 1(3%) 2(6%) 
n (%) 2-3 hrs 3(9%) 1(3%) 
 n (%) 3-4 hrs 6(18%) 9(27%) 
 n (%) 4-5 hrs 9(27%) 7(21%) 
 n (%) 5+ hrs 13(39%) 11(33%) 
Period 2 Mean(SD) 4.36(1.85) 4.13(1.99) 
 n (%) <1 hr 1(3%) 2(6%) 
 n (%) 1-2 hrs 2(6%) 2(6%) 
 n (%) 2-3 hrs 2(6%) 2(6%) 
 n (%) 3-4 hrs 9(28%) 13(40%) 
 n (%) 4-5 hrs 10(31%) 4(13%) 
 n (%) 5+ hrs 8(25%) 9(28%) 
Side effect, no. of patients   
Brace slipping 2 2 
Brace rubbing/irritation 3 3 
Foot/ankle swelling 4 3 
Increased knee pain 4 2 
Other 2 2 
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Figure 3. Interaction between treatment and period effect for VAS Pain. 
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Figure 4. Interaction between treatment and period effect for WOMAC Pain. 
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